Jacob M Hughes

3PUBLICATIONS
21CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Nov 25, 2025
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.

Brianna R Daley, Patricia L Theard, Jacob M Hughes

|Sep 16, 2025
Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers.

Nancy E Sealover, Bridget A Finniff, Jacob M Hughes

|Oct 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma.

Brianna R Daley, Nancy E Sealover, Bridget A Finniff

Pageof 1

Frequent Collaborators

3 joint publications

Robert L Kortum

2 joint publications

Brianna R Daley

2 joint publications

Nancy E Sealover

2 joint publications

Bridget A Finniff

2 joint publications

Erin Sheffels

2 joint publications

Marco H Hofmann

2 joint publications

Kaja Kostyrko

2 joint publications

Joseph P LaMorte

2 joint publications

Amanda Linke

2 joint publications

Matthew D Wilkerson

Frequent Collaborators

3 joint publications

Robert L Kortum

2 joint publications

Brianna R Daley

2 joint publications

Nancy E Sealover

2 joint publications

Bridget A Finniff

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

4.5K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on : Jul 17, 2019

6.5K
Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

17.9K
See more related videos

Top Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

4.5K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on : Jul 17, 2019

6.5K
Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

17.9K
See more related videos